Many employers and government programs won’t cover costly obesity medications. A lawsuit is challenging one such policy.

Experts say the exploitation of a loophole in the patent system has contributed to high prices for inhalers.

The grocery chain, which did not admit wrongdoing, is the latest company accused of helping to fuel the opioid crisis to announce a settlement.

Mallinckrodt Pharmaceuticals had promised $1.7 billion to governments, individuals and others harmed by the opioid crisis.

The company is heavily reliant on a cancer drug that could be targeted by a program intended to lower drug prices.

The Federal Trade Commission said the deal would enable Amgen to “entrench” the monopoly positions of two Horizon drugs that lack competition.

In an unusual court trial, a federal jury sided with the drug maker Gilead Sciences in a dispute over who came up with the idea...

The drug, which will be sold as Qalsody by the pharmaceutical company Biogen, targets a genetic cause of a devastating neurological illness.

The company is the third of the three major insulin manufacturers that dominate the U.S. market to announce such a move this month.

The company’s decision follows a similar move by its rival, Eli Lilly, this month.